Nanobiotix

📍 PARIS, France🗓 Founded 2003👥 122 employees💰 Last funded Apr 2010
Nanotechnology Research🌐 bit.ly
Website LinkedIn
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges. Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. More: www.nanobiotix.com
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Nanobiotix?
Nanobiotix has 1 investors on record on gritt.io and 1 late-stage investors.
When did Nanobiotix last raise funding?
The most recent investment in Nanobiotix recorded on gritt.io was in April 2010.
When was Nanobiotix founded?
Nanobiotix was founded in 2003.
What industry is Nanobiotix in?
Nanobiotix operates in Nanotechnology Research. Find similar Nanotechnology Research investors on gritt.io.
Where is Nanobiotix based?
Nanobiotix is headquartered in PARIS, France.